Guidelines on Muscle-invasive and Metastatic Bladder Cancer
暂无分享,去创建一个
E. Compérat | M. Santis | T. Lebret | G. Gakis | A. Sherif | Eva Comperat | M. De Santis | Georgios Gakis | Thierry Lebret | Amir Sherif
[1] B. Malavaud,et al. Complications for radical cystectomy. Impact of the American Society of Anesthesiologists score. , 2001, European urology.
[2] W. Whitmore,et al. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. , 1985, The Journal of urology.
[3] M. Buglione,et al. Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).
[4] V. Serretta,et al. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. , 2004, European urology.
[5] A. Zlotta. Limited, extended, superextended, megaextended pelvic lymph node dissection at the time of radical cystectomy: what should we perform? , 2012, European urology.
[6] M. Resnick,et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. , 2000, The Journal of urology.
[7] E. Klein,et al. Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder , 2009, Cancer.
[8] M. Soloway,et al. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. , 2008, The Journal of urology.
[9] T. Kälble,et al. Metabolic and functional consequences of urinary reconstruction with bowel , 2003, BJU international.
[10] R. Millikan,et al. Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder , 2010 .
[11] S. Groshen,et al. Radical cystectomy in the elderly , 2005, Cancer.
[12] Joshua R. Ehrlich,et al. A comparison of postoperative complications in open versus robotic cystectomy. , 2010, European urology.
[13] T. Morgan,et al. Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. , 2013, Urology.
[14] U. Nagele,et al. The rationale for radical cystectomy as primary therapy for T4 bladder cancer , 2007, World Journal of Urology.
[15] J. Cordonnier. Urinary diversion. , 1957, Transactions of the American Association of Genito-Urinary Surgeons.
[16] S. Johansson,et al. A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. , 1983, European urology.
[17] G. Lyman,et al. Comorbidity and functional status are independent in older cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Wahlqvist,et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.
[19] D. Byar,et al. Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder. , 1972, The Journal of urology.
[20] H. Miyake,et al. Health-related quality of life after radical cystectomy for bladder cancer: a comparison of ileal conduit and orthotopic bladder replacement , 2002 .
[21] I. Bross,et al. Five‐year follow‐up results of a collaborative study of therapies for carcinoma of the bladder , 1977, Journal of surgical oncology.
[22] Huan-yi Lin,et al. Comparison of surgical stress response to laparoscopic and open radical cystectomy , 2010, World Journal of Urology.
[23] S. Fosså,et al. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. , 1993, Scandinavian journal of urology and nephrology.
[24] M. Milowsky,et al. Detection of circulating tumor cells in patients with urothelial cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] H. Miyake,et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer , 2007, International journal of urology : official journal of the Japanese Urological Association.
[26] J. Stein,et al. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure , 2006, World Journal of Urology.
[27] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[28] C. Rödel,et al. Organ preservation by combined modality treatment in bladder cancer: the European perspective. , 2005, Seminars in radiation oncology.
[29] T. Wilt,et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. , 2015, The Cochrane database of systematic reviews.
[30] U. Egle,et al. Quality of life in patients with bladder carcinoma after cystectomy: First results of a prospective study , 2000, Quality of Life Research.
[31] P. Carroll,et al. Update on chemotherapy for advanced bladder cancer. , 2005, The Journal of urology.
[32] C. Morash,et al. Surveillance strategies after definitive therapy of invasive bladder cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[33] J. Gore,et al. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer , 2013, Advances in urology.
[34] S. Ricci,et al. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .
[35] D. Lubeck,et al. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. , 1999, Urology.
[36] C. Stief,et al. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms , 2010, BJU international.
[37] M. Schrader,et al. The ileal neobladder in female patients with bladder cancer: long-term clinical, functional, and oncological outcome , 2012, World Journal of Urology.
[38] M. Milowsky,et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. , 2009, European urology.
[39] H. von der Maase,et al. Radical radiotherapy for urinary bladder cancer: treatment outcomes , 2006, Expert review of anticancer therapy.
[40] A. Younis,et al. A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer. , 2013, Urologic oncology.
[41] S. Hung,et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. , 2010, The Journal of urology.
[42] M. Fortin,et al. Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. , 2005, Journal of clinical epidemiology.
[43] M. Dimopoulos,et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] P. Bendahl,et al. Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference? , 2009, World Journal of Urology.
[45] J. Witjes,et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. , 1996, AJR. American journal of roentgenology.
[46] E. Wallen,et al. Robotic-assisted laparoscopic intracorporeal urinary diversion. , 2010, European urology.
[47] S. Fosså,et al. Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer. , 1996, British journal of urology.
[48] D. Lubeck,et al. Assessment of prognosis with the total illness burden index for prostate cancer , 2007, Cancer.
[49] E. Barret,et al. Robot-assisted laparoscopic cystoprostatectomy with extended pelvic lymphadenectomy, extracorporeal enterocystoplasty, and intracorporeal enterourethral anastomosis: initial Montsouris experience. , 2010, Journal of endourology.
[50] H. Grossman,et al. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. , 1999, The Journal of urology.
[51] T. Wilt,et al. Surgery versus radiotherapy for muscle invasive bladder cancer? , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).
[52] M. Kuczyk,et al. The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery , 2007, Current opinion in urology.
[53] Christopher J Kane,et al. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. , 2002, The Journal of urology.
[54] A. Prando. Split-bolus MDCT urography: upper tract opacification and performance for upper tract tumors in patients with hematuria , 2010 .
[55] J. Au,et al. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[56] E. Messing,et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. , 2005, Urology.
[57] Y. Yamada,et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. , 2012, International journal of radiation oncology, biology, physics.
[58] V. Guillem,et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Richard H. Cohan,et al. CT urography: definition, indications and techniques. A guideline for clinical practice , 2007, European Radiology.
[60] M. May,et al. Results from three municipal hospitals regarding radical cystectomy on elderly patients. , 2007, International braz j urol : official journal of the Brazilian Society of Urology.
[61] A. Sagalowsky,et al. The diagnosis and treatment of urethral recurrence after radical cystectomy. , 2006, Urologic oncology.
[62] L. Kiemeney,et al. Epidemiology and risk factors of urothelial bladder cancer. , 2013, European urology.
[63] Ji-An Liang,et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. , 2012, European journal of radiology.
[64] H. Grossman,et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. , 2010, The Journal of urology.
[65] R. Sylvester,et al. Intravesical BCG in Patients with Carcinoma in situ of the Urinary Bladder: Long–Term Results of EORTC GU Group Phase II Protocol 30861 , 2001, European Urology.
[66] P. Rochon,et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. , 1996, Medical care.
[67] S. Schoenberg,et al. Whole-body MR imaging of bone marrow. , 2005, European journal of radiology.
[68] P. Russo,et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder , 2008, Cancer.
[69] P. Malmström,et al. Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden , 2013, Scandinavian journal of urology.
[70] M P Lawton,et al. Validation of the Cumulative Illness Rating Scale in a Geriatric Residential Population , 1995, Journal of the American Geriatrics Society.
[71] A. Stenzl,et al. Incidental prostate cancer at radical cystoprostatectomy: implications for apex‐sparing surgery , 2010, BJU international.
[72] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[73] J. Witjes,et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.
[74] H. Hricak,et al. Prospective evaluation of MRI, ¹¹C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. , 2012, European journal of radiology.
[75] F. Algaba,et al. Transitional cell carcinoma of the prostate. , 1985, European urology.
[76] S. Pahernik,et al. Long-term followup of the intussuscepted ileal nipple and the in situ, submucosally embedded appendix as continence mechanisms of continent urinary diversion with the cutaneous ileocecal pouch (Mainz pouch I). , 2006, The Journal of urology.
[77] G. Sonpavde,et al. Neoadjuvant Chemotherapy for Invasive Bladder Cancer , 2012, Current Urology Reports.
[78] F. Saad,et al. Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients. , 2005, The Canadian journal of urology.
[79] R. Hautmann,et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. , 2005, The Journal of urology.
[80] W. Otto,et al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder , 2012, BJU international.
[81] Sten Nilsson,et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. , 2004, European urology.
[82] J. Phillips,et al. The role of perioperative chemotherapy in the treatment of urothelial cancer. , 2006, The oncologist.
[83] B. Herts,et al. The role of computerized tomographic urography in the initial evaluation of hematuria. , 2007, The Journal of urology.
[84] F. Montorsi,et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. , 2013, Cancer epidemiology.
[85] M. Peyromaure,et al. The value of a second transurethral resection in evaluating patients with bladder tumours. , 2003, European urology.
[86] R. C. Coffey. PHYSIOLOGIC IMPLANTATION OF THE SEVERED URETER OR COMMON BILE-DUCT INTO THE INTESTINE , 1911 .
[87] S. Ramsey,et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. , 2011, Urologic oncology.
[88] T. Martini,et al. Comparison of complications in three incontinent urinary diversions. , 2008, European urology.
[89] D. Gillatt,et al. A DELAY IN RADICAL CYSTECTOMY OF >3 MONTHS IS NOT ASSOCIATED WITH A WORSE CLINICAL OUTCOME , 2008, BJU international.
[90] J. Witjes,et al. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. , 2011, European urology.
[91] M. Stöckle,et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. , 1995, The Journal of urology.
[92] W. De Neve,et al. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[93] G. Dalbagni,et al. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. , 2003, The Journal of urology.
[94] N. Shinohara,et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. , 2007, European urology.
[95] T. Kessler,et al. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? , 2010, European urology.
[96] S. Culine,et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] H. Kumon,et al. Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? , 2013, International Journal of Clinical Oncology.
[98] W. Kassouf,et al. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. , 2011, Current oncology.
[99] R. Hohenfellner,et al. Colon pouch (Mainz pouch III) for continent urinary diversion after pelvic irradiation. , 2000, Urology.
[100] R. Hautmann,et al. Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? , 1998, The Journal of urology.
[101] B. I. Choi,et al. Uterine cervical carcinoma: comparison of CT and MR findings. , 1990, Radiology.
[102] J. Stein,et al. Results with radical cystectomy for treating bladder cancer: a ‘reference standard’ for high‐grade, invasive bladder cancer , 2003, BJU international.
[103] J. Witjes,et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. , 2014, European urology.
[104] R. Sylvester,et al. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[105] P. Bassi,et al. Quality of life after radical cystectomy and orthotopic bladder substitution: a comparison between Italian and Swedish men , 2000, BJU international.
[106] J. Damber,et al. A Systematic Overview of Radiation Therapy Effects in Urinary Bladder Cancer , 2003, Acta oncologica.
[107] J. Chang-Claude,et al. Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case‐control studies , 2000, International journal of cancer.
[108] P. Lawler,et al. An assessment of the consistency of ASA physical status classification allocation , 1995, Anaesthesia.
[109] S. Boyd,et al. Radical cystectomy for elderly patients with bladder carcinoma , 1998, Cancer.
[110] B. I. Choi,et al. Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. , 1994, Radiology.
[111] H. G. van der Poel,et al. Short-Term Outcome after Cystectomy: Comparison of Two Different Perioperative Protocols , 2012, Urologia Internationalis.
[112] C. Logothetis,et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] A. Tizzani,et al. Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. , 2008, Urology.
[114] Sam S. Chang,et al. Dilemmas in the treatment of urothelial cancers of the prostate. , 2009, Urologic oncology.
[115] D. Penson,et al. Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. , 2013, The Journal of urology.
[116] Joon-ha Ok,et al. Medical and surgical palliative care of patients with urological malignancies. , 2005, The Journal of urology.
[117] A. Lembo,et al. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. , 2000, The Journal of urology.
[118] F. Burkhard,et al. Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] A. Vickers,et al. Standardization of pelvic lymphadenectomy performed at radical cystectomy , 2006, Cancer.
[120] J. Thüroff,et al. Cancer‐specific survival after radical cystectomy and standardized extended lymphadenectomy for node‐positive bladder cancer: prediction by lymph node positivity and density , 2009, BJU international.
[121] K. Steven,et al. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. , 1998, The Journal of urology.
[122] F. Freiha,et al. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. , 1996, Journal of Urology.
[123] S. Culine,et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[125] S. Altınova,et al. Robot‐assisted nerve‐sparing radical cystectomy with bilateral extended pelvic lymph node dissection (PLND) and intracorporeal urinary diversion for bladder cancer: initial experience in 27 cases , 2012, BJU international.
[126] C. Sternberg,et al. Can patient selection for bladder preservation be based on response to chemotherapy? , 2003, Cancer.
[127] B. Bochner,et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. , 2009, European urology.
[128] F. Porpiglia,et al. Open versus laparoscopy-assisted radical cystectomy: results of a prospective study. , 2007, Journal of endourology.
[129] M. Milowsky,et al. Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits? , 2009, The Journal of urology.
[130] R. Coleman. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.
[131] J. Gabrilove,et al. Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium , 1989 .
[132] A. Zietman,et al. Bladder preservation by combined modality therapy for invasive bladder cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] P. Bassi,et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. , 1999, The Journal of urology.
[134] N. Geller,et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.
[135] D. Margel,et al. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. , 2007, Urology.
[136] N. James,et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer , 2004, British Journal of Cancer.
[137] S. Pahernik,et al. Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs , 2006, World Journal of Urology.
[138] P. Alken,et al. Radical cystectomy--often too late? , 1987, European urology.
[139] S. Groshen,et al. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. , 2004, The Journal of urology.
[140] C. Dinney,et al. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. , 2008, The Journal of urology.
[141] I. Tannock,et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] T. Tanvetyanon. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2005, Cancer.
[143] X. Gamé,et al. Radical Cystectomy in Patients Older than 75 Years: Assessment of Morbidity and Mortality , 2001, European Urology.
[144] N. Vogelzang,et al. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. , 2013, The Journal of urology.
[145] T. Cheung,et al. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. , 2000, AJR. American journal of roentgenology.
[146] J. Bacik,et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] J. Stein. Contemporary concepts of radical cystectomy and the treatment of bladder cancer. , 2003, The Journal of urology.
[148] John T. Wei,et al. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. , 2010, The Journal of urology.
[149] A. Zietman,et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. , 2009, Urology.
[150] W. Mcdougal,et al. Acid-base and electrolyte disorders after urinary diversion , 2004, World Journal of Urology.
[151] M. Babjuk,et al. Guidelines on Urothelial Carcinomas of the Upper Urinary Tract , 2013 .
[152] G. Hortobagyi,et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[153] A. Hemal,et al. Comparison of laparoscopic and open radical cystoprostatectomy for localized bladder cancer with 3-year oncological followup: a single surgeon experience. , 2007, The Journal of urology.
[154] N. Zeybek,et al. Comparison of Ileal Conduit and Transureteroureterostomy with Ureterocutaneostomy Urinary Diversion , 2006, Urologia Internationalis.
[155] R. Cote,et al. Indications for lower urinary tract reconstruction in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens. , 1995, The Journal of urology.
[156] Peter Boyle,et al. Tobacco smoking and cancer: A meta‐analysis , 2008, International journal of cancer.
[157] C. Sternberg,et al. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. , 1995, The Journal of urology.
[158] H. Zincke,et al. Carcinoma in Situ of the Bladder , 1980, Cancer.
[159] A. Feinstein,et al. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. , 1974, Journal of chronic diseases.
[160] E. Wallen,et al. Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. , 2010, Journal of the American College of Surgeons.
[161] H. Rübben,et al. Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. , 2001, Urology.
[162] S. Fosså,et al. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. , 1989, European urology.
[163] Cary Siegel,et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[164] W. Oh,et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[165] Joaquim Bellmunt,et al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. , 2012, European journal of cancer.
[166] L. Bouter,et al. How to measure comorbidity. a critical review of available methods. , 2003, Journal of clinical epidemiology.
[167] L. Kiemeney,et al. Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. , 2012, Urologic oncology.
[168] G. Muto,et al. Stage‐specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy , 2013, International journal of urology : official journal of the Japanese Urological Association.
[169] J. Witjes,et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. , 2009, European urology.
[170] L. Balducci,et al. General guidelines for the management of older patients with cancer. , 2000, Oncology.
[171] J. Witjes,et al. Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice , 2010, Current opinion in urology.
[172] S. Kropf,et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. , 2004, The Journal of urology.
[173] P. Albers,et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). , 2009, European urology.
[174] Sebastien Crouzet,et al. Laparoscopic and robotic assisted radical cystectomy for bladder cancer: a critical analysis. , 2008, European urology.
[175] D. Kroepfl,et al. Radical cystectomy in patients aged ≥ 75 years: an updated review of patients treated with curative and palliative intent , 2005, BJU international.
[176] S. Hutchings,et al. Occupation and cancer in Britain , 2010, British Journal of Cancer.
[177] P. Hoskin,et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[178] S. Santa Cruz,et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[179] Jörg Schmidbauer,et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. , 2004, The Journal of urology.
[180] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[181] B. Ljungberg,et al. Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma , 2009, Scandinavian journal of urology and nephrology.
[182] H. Moch,et al. Patterns of Metastasis in Muscle-Invasive Bladder Cancer (pT2–4): An Autopsy Study on 367 Patients , 1999, Urologia Internationalis.
[183] Alberto Redaelli,et al. Bladder cancer: epidemiology, diagnosis, and management. , 2002, Cancer practice.
[184] C. Sternberg,et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma , 2009, Cancer.
[185] M. Kuczyk,et al. Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. , 2010, International braz j urol : official journal of the Brazilian Society of Urology.
[186] M. D. De Santis,et al. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder , 2007, Current opinion in urology.
[187] W. Huang,et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. , 2003, The Journal of urology.
[188] J. Stein,et al. Indications and technique of the orthotopic neobladder in women. , 2002, The Urologic clinics of North America.
[189] J. Wright,et al. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy , 2008, Cancer.
[190] E. Olcott,et al. Split-bolus MDCT urography with synchronous nephrographic and excretory phase enhancement. , 2007, AJR. American journal of roentgenology.
[191] B. Norlén,et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. , 1999, The Journal of urology.
[192] N. Wiklund,et al. Recent advances in robot-assisted radical cystectomy , 2011, Current opinion in urology.
[193] J. Carles,et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract , 2003, Cancer.
[194] H. Ozen,et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. , 2006, The Journal of urology.
[195] K. Jensen,et al. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery , 2009, BJU international.
[196] R. Wahlqvist,et al. Five-year Followup of a Prospective Trial of Radical Cystectomy and Neoadjuvant Chemotherapy: Nordic Cystectomy Trial 1 , 1996 .
[197] G. Bartsch,et al. The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract? , 1995, The Journal of urology.
[198] A. Zietman,et al. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy , 2000, Annals of medicine.
[199] J. Montie,et al. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. , 2006, The Journal of urology.
[200] A. Papatsoris,et al. Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit? , 2005, Urology.
[201] P. Russo,et al. Cystectomy for bladder cancer: a contemporary series. , 2001, The Journal of urology.
[202] S. Almenar,et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. , 2000, The Journal of urology.
[203] P. Russo,et al. Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. , 2003, The Journal of urology.
[204] C. Bulpitt,et al. Population-based multidimensional assessment of older people in UK general practice: a cluster-randomised factorial trial , 2004, The Lancet.
[205] William A See,et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. , 2008, The Journal of urology.
[206] I. Khubchandani,et al. Neoplasia after ureterosigmoidostomy , 1999, Diseases of the colon and rectum.
[207] V. Reuter,et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. , 1988, The Journal of urology.
[208] J. Brismar,et al. Bone Scintigraphy in Staging of Bladder Carcinoma , 1988, Acta radiologica.
[209] D. Wood,et al. Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. , 2010, Urology.
[210] N. Ikeda,et al. Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma? , 2011, The Annals of thoracic surgery.
[211] Dieter Jocham,et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. , 2003, The Journal of urology.
[212] Yair Lotan,et al. Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy , 2006, Clinical Cancer Research.
[213] S. Daneshmand,et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. , 2011, European urology.
[214] R. Mak,et al. Bladder preservation: optimizing radiotherapy and integrated treatment strategies , 2008, BJU international.
[215] G. Bartsch,et al. Incidence of urethral tumor involvement in 910 men with bladder cancer , 2004, World Journal of Urology.
[216] Jianping Zhang,et al. Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration–voiding–refilling) useful for detecting recurrent bladder cancer? , 2012, Annals of Nuclear Medicine.
[217] B. Redman,et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[218] T. Ratliff. Urine markers for bladder cancer surveillance: a systematic review. , 2005, The Journal of urology.
[219] J. Stein,et al. The orthotopic T pouch ileal neobladder: experience with 209 patients. , 2004, The Journal of urology.
[220] A. Maes,et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. , 2010, European urology.
[221] U. Studer,et al. A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. , 2010, European urology.
[222] J. Stein,et al. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. , 2007, The Journal of urology.
[223] H. Herr,et al. The value of a second transurethral resection in evaluating patients with bladder tumors. , 2000, The Journal of urology.
[224] T. Kälble,et al. Tumor induction and prophylaxis following different forms of intestinal urinary diversion in a rat model , 2004, Urological Research.
[225] L. Sharples,et al. Performance status score: do patients and their oncologists agree? , 2003, British Journal of Cancer.
[226] E. Wallen,et al. Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. , 2010, The Journal of urology.
[227] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[228] S. Groshen,et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[229] M. Thun,et al. Tobacco smoke and involuntary smoking. , 2004, IARC monographs on the evaluation of carcinogenic risks to humans.
[230] I. Näslund,et al. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. , 1994, Acta oncologica.
[231] A. Pollack,et al. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. , 1996, Seminars in urologic oncology.
[232] G. Raj,et al. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[233] J. Debatin,et al. Whole-body MR imaging: evaluation of patients for metastases. , 2004, Radiology.
[234] G. Scagliotti,et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[235] Peter A. Jones,et al. Molecular targets and targeted therapies in bladder cancer management , 2008, World Journal of Urology.
[236] H. Herr,et al. Conservative management of muscle-infiltrating bladder cancer: prospective experience. , 1987, The Journal of urology.
[237] A. Vickers,et al. Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder , 2006, Cancer.
[238] A L Baert,et al. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. , 1994, Radiology.
[239] M. Gerken,et al. Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers , 2008, World Journal of Urology.
[240] N. Shakhssalim,et al. Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. , 2009, Urology journal.
[241] W. Meinhardt,et al. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[242] S. Phillips,et al. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. , 2011, The Journal of urology.
[243] R. Sylvester,et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[244] F. Montorsi,et al. Stage‐specific impact of pelvic lymph node dissection on survival in patients with non‐metastatic bladder cancer treated with radical cystectomy , 2012, BJU international.
[245] U. Ha,et al. Laparoscopic versus open radical cystectomy for the management of bladder cancer: Mid‐term oncological outcome , 2010, International journal of urology : official journal of the Japanese Urological Association.
[246] H. Scher,et al. Surgery of invasive bladder cancer: is pathologic staging necessary? , 1990, Seminars in oncology.
[247] R. Fimmers,et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[248] M. Zaghloul. The need to revisit adjuvant and neoadjuvant radiotherapy in bladder cancer , 2010, Expert review of anticancer therapy.
[249] S. Donat. Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective? , 2006, World Journal of Urology.
[250] C. Siegel. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. , 2005, The Journal of urology.
[251] L. Collette,et al. Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy. , 2006, European urology.
[252] J. B. Jensen,et al. Extended versus limited lymph node dissection in radical cystectomy: Impact on recurrence pattern and survival , 2012, International journal of urology : official journal of the Japanese Urological Association.
[253] C. Rödel,et al. Trimodality treatment and selective organ preservation for bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[254] R. Autorino,et al. Health related quality of life after radical cystectomy: comparison of ileal conduit to continent orthotopic neobladder. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[255] J. Huguet. Follow-up after radical cystectomy based on patterns of tumor recurrence and its risk factors , 2013 .
[256] S. Nilsson,et al. Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. , 1994, British journal of urology.
[257] J. Dunn,et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. , 1991, British journal of urology.
[258] J. Muscat,et al. Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. , 1998, Anticancer research.
[259] J. Montie. Intravesical bacille calmette-guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. , 2005, The Journal of urology.
[260] R. Sylvester,et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[261] J. Ware,et al. Evaluating Translations of Health Status Questionnaires: Methods From the IQOLA Project , 1995, International Journal of Technology Assessment in Health Care.
[262] P. Schellhammer,et al. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. , 2007, Clinical genitourinary cancer.
[263] B. Guillonneau,et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. , 2002, The Journal of urology.
[264] L. Kiemeney,et al. The present and future burden of urinary bladder cancer in the world , 2009, World Journal of Urology.
[265] Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. , 1994, IARC monographs on the evaluation of carcinogenic risks to humans.
[266] R. Hautmann,et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. , 2013, European urology.
[267] F. Burkhard,et al. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. , 2004, The Journal of urology.
[268] M. Mazumdar,et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[269] Y. Lotan,et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. , 2010, The Journal of urology.
[270] J. Morley,et al. Controlled Trial of a Geriatric Case‐Finding and Liaison Service in an Emergency Department , 1996, Journal of the American Geriatrics Society.
[271] H. Scher,et al. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[272] S. Almenar,et al. The optimum timing of radical cystectomy for patients with recurrent high‐risk superficial bladder tumour , 2004, BJU international.
[273] A. Pycha,et al. Four years experience in bladder preserving management for muscle invasive bladder cancer. , 2005, European urology.
[274] S. Groshen,et al. Urethral recurrence in patients with orthotopic ileal neobladders. , 1996, The Journal of urology.
[275] S. Shariat,et al. Stage specific lymph node metastasis mapping in radical cystectomy specimens. , 2004, The Journal of urology.
[276] M. Ghoneim,et al. Functional results of orthotopic ileal neobladder with serous-lined extramural ureteral reimplantation: experience with 450 patients. , 2001, The Journal of urology.
[277] Y. Lotan,et al. Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival , 2010, BJU international.
[278] C. Lawton. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer , 2009 .
[279] B. Gross,et al. Upper abdominal lymph nodes: criteria for normal size determined with CT. , 1991, Radiology.
[280] D. Johnson,et al. Long-term results following thoracotomy for metastatic bladder cancer. , 1982, Urology.
[281] Eiji Kikuchi,et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. , 2011, AJR. American journal of roentgenology.
[282] Yusuke Nakamura,et al. Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapy , 2007, Cancer science.
[283] Vikas Kundra,et al. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. , 2007, AJR. American journal of roentgenology.
[284] F. Freiha,et al. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. , 1993, The Journal of urology.
[285] R. Fisher,et al. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. , 1995, International journal of radiation oncology, biology, physics.
[286] W. Otto,et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. , 2012, European urology.
[287] M. Melekos,et al. Ten Years’ Experience with the Submucosally Embedded in situ Appendix in Continent Cutaneous Diversion , 2001, European Urology.
[288] F. Montorsi,et al. Development and Validation of a Reference Table for Prediction of Postoperative Mortality Rate in Patients Treated with Radical Cystectomy: A Population-based Study , 2011, Annals of Surgical Oncology.
[289] R. Svatek,et al. Role and Extent of Lymphadenectomy During Radical Cystectomy for Invasive Bladder Cancer , 2012, Current Urology Reports.
[290] B. Linn,et al. CUMULATIVE ILLNESS RATING SCALE , 1968, Journal of the American Geriatrics Society.
[291] G. Sonpavde,et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. , 2011, The Lancet. Oncology.
[292] S. Holmäng,et al. Long-term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. , 1997, The Journal of urology.
[293] S. Groshen,et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[294] J. Montie,et al. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. , 2003, The Urologic clinics of North America.
[295] L. Lawler. MR imaging of the bladder. , 2003, Radiologic clinics of North America.
[296] A. Pycha,et al. Does extended lymphadenectomy increase the morbidity of radical cystectomy? , 2004, BJU international.
[297] J. Huguet,et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. , 2005, European urology.
[298] N. Cowan. CT urography for hematuria , 2012, Nature Reviews Urology.
[299] Yusuke Nakamura,et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[300] Does Radical Cystectomy Improve Overall Survival in Octogenarians with Muscle-Invasive Bladder Cancer? , 2011, Korean journal of urology.
[301] Gerhard Jakse,et al. A second-look TUR in T1 transitional cell carcinoma: why? , 2004, European urology.
[302] Y. Lotan,et al. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome , 2007, BJU international.
[303] S. Fosså,et al. Clinical significance of the "palpable mass" in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. , 1991, British journal of urology.
[304] F. Burkhard,et al. Long-term outcome of ileal conduit diversion. , 2003, The Journal of urology.
[305] R. Hautmann,et al. 25 years of experience with 1,000 neobladders: long-term complications. , 2011, The Journal of urology.
[306] I. Tannock,et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. , 2007, Urologic oncology.
[307] Z. Piao,et al. Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: Case report and literature review , 2012, Surgical neurology international.
[308] E. Lindholm,et al. Long–Time Experience with the Kock Ileal Reservoir for Continent Urinary Diversion , 2001, European Urology.
[309] R. Hautmann,et al. Long-term results of standard procedures in urology: the ileal neobladder , 2006, World Journal of Urology.
[310] N. Cowan,et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour , 2007, BJU international.
[311] P. Dahm,et al. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. , 2002, European urology.
[312] S. Groshen,et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction , 1995, Cancer.
[313] I. Tannock,et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[314] F. Wiklund,et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder , 2005, Scandinavian journal of urology and nephrology.
[315] R. Fimmers,et al. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). , 2011, European urology.
[316] U. Studer,et al. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[317] P. Tanis,et al. Surgery for isolated lung metastasis in two patients with bladder cancer. , 2005, Urology.
[318] R. Kuefer,et al. Oncological followup after radical cystectomy for bladder cancer-is there any benefit? , 2009, The Journal of urology.
[319] E. Tuzel,et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. , 2005, European urology.
[320] M. Lucia,et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. , 2011, Urology.
[321] M. Higashiyama,et al. Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma. , 2010, Interactive cardiovascular and thoracic surgery.
[322] A. Vickers,et al. Age‐adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer , 2008, Cancer.
[323] A R Feinstein,et al. THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE. , 1970, Journal of chronic diseases.
[324] J. Hainsworth,et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[325] R. Bahnson,et al. EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER , 2000 .
[326] P. Boström,et al. Risk factors for mortality and morbidity related to radical cystectomy , 2009, BJU international.
[327] George Gayagay,et al. Validation of the Cumulative Illness Rating Scale (CIRS) in hospitalized nonagenarians. , 2007, Archives of gerontology and geriatrics.
[328] C. Tangen,et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. , 2009, Urologic oncology.
[329] P. Carroll,et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.
[330] M. Stöckle,et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. , 2010, Neoplasia.
[331] L. Seymour,et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. , 2002, Urologic oncology.
[332] D. Penson,et al. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. , 2005, The Journal of urology.
[333] H. Loertzer,et al. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. , 2000, The Journal of urology.
[334] J. Portillo,et al. Original Articles: Bladder Cancer: Neoadjuvant Cisplatin Chemotherapy Before Radical Cystectomy in Invasive Transitional Cell Carcinoma of the Bladder: A Prospective Randomized Phase III Study , 1995 .
[335] E. Solsona,et al. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. , 2010, The Journal of urology.
[336] Yair Lotan,et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. , 2006, The Journal of urology.
[337] Matthias Egger,et al. Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. , 2002, JAMA.
[338] E. Ioachim,et al. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components , 2006, BMC Cancer.
[339] D. Penson,et al. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. , 2009, The Journal of urology.
[340] V. Ficarra,et al. Complications and mortality after radical cystectomy for bladder transitional cell cancer. , 2009, The Journal of urology.
[341] M. Ghoneim,et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. , 2008, The Journal of urology.
[342] H. Grossman,et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. , 2007, The Journal of urology.
[343] C. Sternberg,et al. Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy , 2001, Cancer.
[344] G. Bartsch,et al. Original Articles: Bladder Cancer: The Risk of Urethral Tumors in Female Bladder Cancer: Can the Urethra be Used for Orthotopic Reconstruction of the Lower Urinary Tract? , 1995 .
[345] W. Whitmore,et al. Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. , 1977, Transactions of the American Association of Genito-Urinary Surgeons.
[346] W. Mcdougal. The continent urinary diversion. , 1987, The Journal of urology.
[347] P. Franzone,et al. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. , 1995, International journal of radiation oncology, biology, physics.
[348] D. Lamm,et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.
[349] G. Muto,et al. Complications following radical cystectomy for bladder cancer in the elderly. , 2009, European urology.
[350] M. Grimm,et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. , 2003, The Journal of urology.
[351] M. Mencoboni,et al. Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric , 2004, Oncology.
[352] Stefano Galli,et al. A cost comparison of laparoscopic versus open radical cystoprostatectomy and orthotopic ileal neobladder at a single institution. , 2007, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[353] L. Collette,et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[354] H. von der Maase,et al. Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. , 2007, European urology.
[355] J. Carles,et al. Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function , 2006 .
[356] R. Hautmann,et al. Lessons learned from 1,000 neobladders: the 90-day complication rate. , 2010, The Journal of urology.
[357] A Rajesh,et al. Bladder cancer: evaluation of staging accuracy using dynamic MRI. , 2011, Clinical radiology.
[358] R. Hautmann,et al. A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? , 2010, European urology.
[359] K. Golka,et al. N-Acetyltransferase-2 and Medical History in Bladder Cancer Cases with a Suspected Occupational Disease (BK 1301) in Germany , 2008, Journal of toxicology and environmental health. Part A.
[360] R. Millikan,et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? , 2003, The Journal of urology.
[361] M. Babjuk,et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. , 2012, European urology.
[362] M. Krzakowski,et al. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.
[363] R. Autorino,et al. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. , 2007, European urology.
[364] H. Habermann,et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? , 2002, Urology.
[365] S. Groshen,et al. Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer. , 1990, Seminars in urology.
[366] Ashesh B Jani,et al. An electronic application for rapidly calculating Charlson comorbidity score , 2004, BMC Cancer.
[367] N Karssemeijer,et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. , 1996, Radiology.
[368] H. G. van der Poel,et al. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. , 2008, European urology.
[369] M. Stöckle,et al. Complete long‐term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer , 2006, BJU international.
[370] L. Carmignani,et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. , 2012, The Journal of urology.
[371] J. Witjes,et al. Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT , 2004, European Radiology.
[372] John T. Wei,et al. The impact of co-morbid disease on cancer control and survival following radical cystectomy. , 2003, The Journal of urology.
[373] T. Lebret,et al. Urethral Recurrence of Transitional Cell Carcinoma of the Bladder , 1998, European Urology.
[374] C. Hodges,et al. Radical cystectomy for bladder cancer. , 1978, The Journal of urology.
[375] J. Paradelo,et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. , 1997, The Journal of urology.
[376] M. Extermann,et al. Management of cancer in the older person: a practical approach. , 2000, The oncologist.
[377] D. Roychowdhury,et al. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[378] J. Dunst,et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[379] J. Eastham. Do high-volume hospitals and surgeons provide better care in urologic oncology? , 2009, Urologic oncology.
[380] J. Birkmeyer,et al. Trends in hospital volume and operative mortality for high-risk surgery. , 2011, The New England journal of medicine.
[381] P. Carroll,et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. , 1994, Radiology.
[382] E. Klein,et al. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. , 2008, Journal of Urology.
[383] Franz Quehenberger,et al. Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract , 2006, European Radiology.
[384] Sam S. Chang,et al. Volume outcomes of cystectomy--is it the surgeon or the setting? , 2012, The Journal of urology.
[385] D. Lamm,et al. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.
[386] P. Dasgupta,et al. The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. , 2011, European urology.
[387] J. Stockman,et al. Association Between Smoking and Risk of Bladder Cancer Among Men and Women , 2013 .
[388] M. Schwaiger,et al. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. , 2012, European urology.
[389] Andreas Böhle,et al. Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS) , 2014 .
[390] J. Carles,et al. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. , 2012, European journal of cancer.
[391] J. Huguet,et al. Management of urethral recurrence in patients with Studer ileal neobladder. , 2003, European urology.
[392] S. Groshen,et al. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. , 1999, The Journal of urology.
[393] J. Bellmunt,et al. New therapeutic challenges in advanced bladder cancer. , 2012, Seminars in oncology.
[394] P. Sogani,et al. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? , 2001, The Journal of urology.
[395] A. Goel,et al. Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-11. , 2012, European urology.
[396] U. Nagele,et al. Cystectomy – Technical Considerations in Male and Female Patients , 2005 .
[397] P. Lavori,et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. , 2002, The New England journal of medicine.
[398] Å. Månsson,et al. The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference? , 2002, BJU international.
[399] P. Albers,et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[400] M. R. W. Engelbrecht,et al. MR imaging of the male pelvis , 1999, European Radiology.
[401] J. Gore,et al. Mortality increases when radical cystectomy is delayed more than 12 weeks , 2009, Cancer.
[402] R. Sylvester,et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[403] H. Thomsen,et al. Nephrogenic systemic fibrosis: history and epidemiology. , 2009, Radiologic clinics of North America.
[404] Pierre I Karakiewicz,et al. A population‐based competing‐risks analysis of the survival of patients treated with radical cystectomy for bladder cancer , 2011, Cancer.
[405] G. Dalbagni,et al. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. , 2003, The Journal of urology.
[406] S Majewski,et al. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[407] M. Benson,et al. Muscle-invasive urothelial carcinoma of the bladder. , 2007, Urology.
[408] G. Muto,et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[409] T. Ahlering,et al. Laparoscopic assisted radical cystectomy with ileal neobladder: a comparison with the open approach. , 2004, The Journal of urology.
[410] Y. Lotan,et al. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy , 2013, BJU international.
[411] J. Stein,et al. Complications of radical cystectomy. , 2007, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
[412] R. Hautmann,et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. , 2012, European urology.
[413] Michael Cookson,et al. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. , 2002, The Journal of urology.
[414] N. Clarke,et al. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. , 2010, European urology.
[415] O. Hughes,et al. Safety and feasibility of laparoscopic radical cystectomy for the treatment of bladder cancer. , 2013, Journal of endourology.
[416] P. Clark. Radical cystectomy for carcinoma of the bladder. , 1978, British journal of urology.
[417] J. Witjes,et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. , 1998, Radiology.
[418] Y. Osman,et al. Bladder cancer with obstructive uremia: oncologic outcome after definitive surgical management. , 2005, Urology.
[419] Yair Lotan,et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. , 2006, The Journal of urology.
[420] J. Witjes,et al. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. , 2012, European urology.
[421] D. Bajorin,et al. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. , 2001, The Journal of urology.
[422] S. Culine,et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen , 2006, British Journal of Cancer.
[423] D. Ackermann,et al. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder. , 1995, British journal of urology.
[424] V. Paleri,et al. Applicability of the adult comorbidity evaluation – 27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study , 2002, The Journal of Laryngology & Otology.
[425] A. Sagalowsky,et al. Prevention and management of complications following radical cystectomy for bladder cancer. , 2010, European urology.
[426] P. Albers,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[427] L. Mazzucchelli,et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. , 1994, The Journal of urology.
[428] A. Böhle,et al. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. , 2004, Urology.
[429] Sam S. Chang,et al. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. , 2003, The Journal of urology.
[430] R. Millikan,et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. , 2004, The Journal of urology.
[431] P. Vock,et al. Is ileal orthotopic bladder substitution with an afferent tubular segment detrimental to the upper urinary tract in the long term? , 2002, The Journal of urology.
[432] M. Dimopoulos,et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[433] Çağatay Göğüş,et al. The significance of random bladder biopsies in superficial bladder cancer , 2004, International Urology and Nephrology.
[434] O. S. Nielsen,et al. Neoadjuvant Chemotherapy with Cisplatin and Methotrexate in Patients with Muscle-Invasive Bladder Tumours , 2002, Acta oncologica.
[435] H. von der Maase,et al. Metastatic Urothelial Cancer: Evaluation of Prognostic Factors and Change in Prognosis during the Last Twenty Years , 2001, European Urology.
[436] E. Skinner,et al. Quality of life after cystectomy and urinary diversion: an evidence based analysis. , 2005, The Journal of urology.
[437] Greenberg,et al. Management of Cancer in the Older Aged Person. , 1994, Cancer Control: Journal of the Moffitt Cancer Cente.
[438] D. Wood,et al. Stomal complications of ileal conduits are significantly higher when formed in women with intractable urinary incontinence. , 2004, The Journal of urology.
[439] T. Lebret,et al. The Z‐shaped ileal neobladder after radical cystectomy: an 18 years experience with 329 patients , 2011, BJU international.
[440] I. Näslund,et al. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. , 1998, British journal of urology.
[441] C. Sternberg,et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. , 2002, Urology.
[442] P. Albers,et al. Randomised phase II trial of gemcitabine and paclitaxel second‐line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99) , 2005, International journal of clinical practice.
[443] G. Jakse,et al. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? , 2001, The Journal of urology.
[444] G. Bartsch,et al. Life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. , 2001, Seminars in urologic oncology.
[445] Sam S. Chang,et al. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. , 2003, The Journal of urology.
[446] S Greenfield,et al. The Importance of Co-existent Disease in the Occurrence of Postoperative Complications and One-Year Recovery in Patients Undergoing Total Hip Replacement: Comorbidity and Outcomes After Hip Replacement , 1993, Medical care.